Session » Pediatric Rheumatology – Basic Science Poster

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1778

A Novel Variant in IRAK2 Results in Immune Dysregulation in Systemic Juvenile Idiopathic Arthritis (sJIA)

10:30AM-12:30PM: Abstract Number: 1768

A Potential Role of Longstanding IL-18 Stimulation in the Susceptibility for Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 1776

Animal Models of Pediatric MOGAD

10:30AM-12:30PM: Abstract Number: 1770

Assessing S100A4 and Myofibroblast Phenotypes in the Pathogenesis of Cardiac and Cutaneous Neonatal Lupus

10:30AM-12:30PM: Abstract Number: 1777

Broad Proteomic Analysis Reveals Top Differential Protein Modules and Functional Annotations with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups

10:30AM-12:30PM: Abstract Number: 1765

CD8+ T Cells and Monocytes from Children with Macrophage Activation Syndrome Demonstrate Specific Transcriptional Changes Consistent with T Cell Activation and Expansion of Monocytes Shaped by Interferon and TLR Signaling

10:30AM-12:30PM: Abstract Number: 1771

Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics

10:30AM-12:30PM: Abstract Number: 1775

Childhood-onset Sjögren Disease Has an Altered Peripheral Blood Immune Landscape Compared to Adult-onset Disease Characterized by Activated CD4+ T-cells Which Could Drive B-cell Dysregulation

10:30AM-12:30PM: Abstract Number: 1763

Circulating NK and CD8+ Cytotoxic T Cells in Treatment Naïve JDM Demonstrate Higher Cytotoxic and Interferon Signature as Compared to Childhood-Onset SLE

10:30AM-12:30PM: Abstract Number: 1773

Divergent Genetic Architecture in Boys and Girls with NEMO-deleted Exon 5 Autoinflammatory Syndrome (NEMO-NDAS) Implies Role for Wildtype Effector Cells

10:30AM-12:30PM: Abstract Number: 1782

DOCK2 Mutations and Hyper-Inflammatory Syndromes

10:30AM-12:30PM: Abstract Number: 1767

Endothelial Cell-Driven JAG/NOTCH Signaling in Localized Scleroderma Patients

10:30AM-12:30PM: Abstract Number: 1761

Juvenile Idiopathic Arthritis Genetic Risk Haplotypes: Relevance to Children of African Ancestry

10:30AM-12:30PM: Abstract Number: 1774

Metabolomics and Lipidomics in Juvenile Localized Scleroderma

10:30AM-12:30PM: Abstract Number: 1772

Modeling and Predicting HLH Through Measurement of Immune Synapse Duration, Cytokine Production, and Target Cell Death

10:30AM-12:30PM: Abstract Number: 1782.5

Monocytes from HLA B27 Positive Enthesitis Related Arthritis Patients Are More Activated Than HLA B27 Negative Patients

10:30AM-12:30PM: Abstract Number: 1762

Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk

10:30AM-12:30PM: Abstract Number: 1780

Next Generation Sequencing Analysis Reveals Complex Genetic Architecture of Childhood-onset Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1764

Reduction in Circulating Neutrophil Extracellular Traps and Restored Degradation Post-treatment in Pediatric Lupus

10:30AM-12:30PM: Abstract Number: 1779

Single-Nuclear RNA-Sequencing of Treatment Naïve JDM Muscle Highlights Dysregulated Vascular Integrity and Angiogenesis in Endothelial Cells and Decreased Nitric Oxide Synthase Signaling in Type II Muscle Fibers

10:30AM-12:30PM: Abstract Number: 1766

STAT2-Associated Type I Interferonopathy: A Masquerade of Infectious Susceptibility

10:30AM-12:30PM: Abstract Number: 1781

Tear Proteomics as a Classifier of Disease Type and Activity Status in Pediatric Uveitis

10:30AM-12:30PM: Abstract Number: 1769

Top Peripheral Blood Transcriptomic Gene Modules Reveal Functional Annotation and Correlation with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].